Vulcan Value Partners LLC Acquires 125,464 Shares of Elevance Health, Inc. $ELV

Vulcan Value Partners LLC lifted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 42.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 419,195 shares of the company’s stock after purchasing an additional 125,464 shares during the period. Elevance Health accounts for 2.5% of Vulcan Value Partners LLC’s holdings, making the stock its 12th biggest holding. Vulcan Value Partners LLC owned about 0.19% of Elevance Health worth $135,706,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vestmark Advisory Solutions Inc. lifted its holdings in Elevance Health by 79.6% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 3,371 shares of the company’s stock worth $1,089,000 after buying an additional 1,494 shares during the period. Channing Capital Management LLC raised its position in shares of Elevance Health by 32.6% during the third quarter. Channing Capital Management LLC now owns 36,049 shares of the company’s stock worth $11,648,000 after acquiring an additional 8,861 shares during the last quarter. Michels Family Financial LLC bought a new position in shares of Elevance Health during the third quarter worth about $745,000. Lansforsakringar Fondforvaltning AB publ lifted its stake in shares of Elevance Health by 3.2% in the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 72,614 shares of the company’s stock worth $23,463,000 after acquiring an additional 2,280 shares during the period. Finally, Rossby Financial LCC boosted its holdings in Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Performance

ELV opened at $342.95 on Monday. The company has a market cap of $75.69 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 1.90 and a beta of 0.50. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company’s fifty day moving average price is $352.37 and its two-hundred day moving average price is $334.71.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same period in the previous year, the company posted $3.84 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Robert W. Baird raised their price target on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Truist Financial decreased their price objective on shares of Elevance Health from $400.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Jefferies Financial Group lowered their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Leerink Partners upped their price target on shares of Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a research report on Thursday, January 29th. Finally, Barclays decreased their price target on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.